To Assess the Safety, Reactogenicity & Immunogenicity of a 4th Dose of GSK Biologicals' Pneumococcal Vaccine or Prevenar in Children (12-18 Months) Previously Vaccinated in the Primary Study NCT00307554 With Either Pneumococcal Vaccine or Prevenar
Latest Information Update: 25 Jul 2023
At a glance
- Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Hib-DTaP-hepatitis B-poliovirus vaccine; Pneumococcal 7-valent CRM197 vaccine conjugate
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Pneumococcal infections; Poliomyelitis; Streptococcal infections; Tetanus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 03 Apr 2013 New trial record